Quantbot Technologies LP Invests $880,000 in Xeris Biopharma Holdings, Inc. $XERS

Quantbot Technologies LP bought a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 111,102 shares of the company’s stock, valued at approximately $880,000. Quantbot Technologies LP owned approximately 0.06% of Xeris Biopharma as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. BlackRock Inc. bought a new position in Xeris Biopharma during the 2nd quarter valued at $115,042,000. Vanguard Group Inc. grew its stake in shares of Xeris Biopharma by 13.8% in the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after acquiring an additional 1,358,760 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Xeris Biopharma by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock worth $33,571,000 after acquiring an additional 135,815 shares in the last quarter. State Street Corp raised its holdings in shares of Xeris Biopharma by 10.1% in the fourth quarter. State Street Corp now owns 4,116,924 shares of the company’s stock valued at $32,318,000 after purchasing an additional 378,595 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its position in shares of Xeris Biopharma by 6.0% during the third quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock valued at $26,657,000 after purchasing an additional 185,063 shares in the last quarter. Institutional investors own 42.75% of the company’s stock.

Insider Activity at Xeris Biopharma

In related news, Director John Johnson sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total value of $91,350.00. Following the completion of the transaction, the director directly owned 683,083 shares of the company’s stock, valued at approximately $4,159,975.47. This trade represents a 2.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,666 shares of Xeris Biopharma stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $8.01, for a total transaction of $133,494.66. Following the completion of the transaction, the insider owned 1,144,462 shares of the company’s stock, valued at $9,167,140.62. This represents a 1.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 271,499 shares of company stock worth $2,038,917 in the last ninety days. Insiders own 4.35% of the company’s stock.

Analyst Upgrades and Downgrades

XERS has been the topic of a number of research analyst reports. Wall Street Zen downgraded Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, Barclays lifted their price objective on shares of Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $12.00.

Xeris Biopharma Stock Down 0.7%

XERS stock opened at $8.68 on Thursday. The stock has a fifty day moving average of $8.22 and a 200-day moving average of $6.90. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $5.25 and a fifty-two week high of $10.08. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of -78.91 and a beta of 0.66. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.19). The business had revenue of $92.10 million for the quarter, compared to analysts’ expectations of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. As a group, equities research analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.